News around the world


Mayo clicnic researcher uses supercomputer to model a SARS viral enzyme
Mayo clinic researcher, Dr Yuan-Ping Pang, a chemist and head of the Computer-Aided Molecular Design Laboratory, has developed a series of three-dimensional (3D) models of an enzyme responsible for the replication of the deadly Severe Acute Respiratory Syndrome (SARS) virus. These instantaneous “structures-in-time” are central to designing an anti-SARS drug – and are therefore a welcomed advance as the virus continues to threaten public health.

The structure and dynamics of the SARS viral enzyme, called chymotrypsin-like cysteine proteinase, is described in the online version of the journal Proteins: Structure, Function and Bioinformatics.


UK grants human cloning licence
Britain has granted its first license for therapeutic cloning on 11th August 2004, more than three years after becoming the first nation to authorize the technique to produce stem cells for medical research. “After careful consideration of all the scientific, ethical, legal and medical aspects of the project, the Human Fertilization and Embryology Authority License Committee agreed to grant an initial one year research to the Newcastle Centre for Life,” the British regulator said. The researchers of Newcastle University hope to create insulin-producing cells that could be transplanted into diabetic patients.

On a related front, Britain’s leading scientific institution said it is urging countries to back a campaign to stop a possible ban on human cloning as part of global treaty banning human cloning on 30th August 2004. The London-based Royal Society is stepping up its drive to push the United Nations to ban the cloning of babies, but to make no ruling on using the technology for medical research, or therapeutic cloning, at its 59th General Session in October 2004.


Europe gives GM green light
The European Commission authorized the first Genetically Modified (GM) seeds for commercial use across European Union (EU) territory on 8th September 2004. A total of 17 GM maize (MON810) varieties have been added to the EU Common Seed Catalogue, and a strain of GM oilseed rape were approved for sale, allowing trade and planting of these varieties in all 25 EU Member States.

David Byrne, the European Commissioner for Health and Consumer Protection, said in a press release that the maize has been "thoroughly assessed to be safe for human health and the environment. It has been grown in Spain for years without any known problems; it will be clearly labeled as GM maize to allow farmers a choice.”

To view common question and answers on the regulation of GMOs in the EU, please click here.

< Back to frontpage

Next >